Published in Proc Soc Exp Biol Med on October 01, 1970
Effect of double-stranded viral RNA on mammalian cells in culture. Proc Natl Acad Sci U S A (1971) 1.42
Antiviral activity and side effects of polyriboinosinic-cytidylic acid complexes as affected by molecular size. Proc Natl Acad Sci U S A (1972) 0.93
Changing the actions of neuroactive drugs by changing brain protein synthesis. Proc Natl Acad Sci U S A (1974) 0.85
Tumor angiogenesis factor. Speculations on an approach to cancer chemotherapy. Yale J Biol Med (1974) 0.79
Replication of semliki forest virus: three forms of viral RNA produced during infection. Proc Natl Acad Sci U S A (1966) 3.23
A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates. J Infect Dis (1975) 2.14
Inhibition of tumor growth by polyinosinic-polycytidylic acid. Proc Natl Acad Sci U S A (1969) 2.00
Molecular basis of the action of interferon. J Mol Biol (1968) 1.70
Interferon preparations as modifiers of immune responses. Proc Soc Exp Biol Med (1972) 1.44
The recognition of viral RNA by mammalian ribosomes. An effect of interferon. Biochim Biophys Acta (1968) 1.44
Ribosomes: effect of interferon on their interaction with rapidly labeled cellular and viral RNA's. Science (1967) 1.44
A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors. J Natl Cancer Inst (1976) 1.42
Inhibition of biologic activity of poly I: poly C by human plasma. Proc Soc Exp Biol Med (1970) 1.42
Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study. Neurosurgery (1996) 1.39
Successful prophylaxis against rabies in mice and Rhesus monkeys: the interferon system and vaccine. J Infect Dis (1977) 1.33
Some factors affecting the interferon-induced antiviral state. Proc Soc Exp Biol Med (1967) 1.33
Effect of interferon on early interferon production. Science (1966) 1.30
Interferon action on parental Semliki forest virus ribonucleic acid. J Virol (1967) 1.28
Effect of a nuclease-resistant derivative of polyriboinosinic-polyribocytidylic acid complex on yellow fever in rhesus monkeys (Macaca mulatta). J Infect Dis (1977) 1.19
An interdisciplinary method of classifying and monitoring medication errors. Am J Hosp Pharm (1985) 1.19
The effect of polyinosinic-polycytidylic acid upon graft-vs-host activity in BALB/c mice. J Immunol (1970) 1.18
Interferon and uninfected cells. Proc Soc Exp Biol Med (1966) 1.15
Modification of chronic hepatitis-B virus infection in chimpanzees by administration of an interferon inducer. Lancet (1976) 1.10
Interferon: lack of detectable uptake by cells. Science (1966) 1.09
Modified polyriboinosinic-polyribocytidylic acid, an immunological adjuvant. Infect Immun (1976) 1.09
Interferon and interferon inducers in the treatment of malignancies. Arch Intern Med (1970) 1.08
Protective and toxic effects of a nuclease-resistant derivative of polyriboinosinic-polyribocytidylic acid on Venezuelan equine encephalomyelitis virus in rhesus monkeys. J Infect Dis (1979) 1.07
Modified polyriboinosinic-polyribocytidylic acid complex: sustained interferonemia and its physiological associates in humans. Infect Immun (1979) 1.05
Prophylactic and therapeutic efficacies of poly(IC.LC) against respiratory influenza A virus infection in mice. Antimicrob Agents Chemother (1995) 1.04
Swine influenza virus vaccine: potentiation of antibody responses in rhesus monkeys. Science (1977) 1.03
Lack of correlation between interferon induction and antitumour effect of poly I-poly C. Nat New Biol (1971) 1.02
Initial clinical trials in cancer patients of polyriboinosinic-polyribocytidylic acid stabilized with poly-L-lysine, in carboxymethylcellulose [poly(ICLC)], a highly effective interferon inducer. Cancer Res (1979) 1.01
Interferon induction in cynomolgus and rhesus monkey after repeated doses of a modified polyriboinosinic-polyribocytidylic acid complex. Antimicrob Agents Chemother (1977) 1.01
Phase I-II trials of poly IC stabilized with poly-L-lysine. Cancer Treat Rep (1978) 1.00
A preliminary trial of poly(I,C)-LC in multiple sclerosis. J Biol Response Mod (1985) 0.99
Postinfectious encephalopathy after treatment of herpes simplex encephalitis with acyclovir. Pediatr Infect Dis (1984) 0.99
The effect of interferon, interferon inducers or interferon induced virus resistance on subsequent interferon production. J Gen Virol (1972) 0.97
Induction of interferon in lymphoblastoid cell lines. Proc Soc Exp Biol Med (1970) 0.96
Interferon. Annu Rev Microbiol (1966) 0.95
Mechanisms of DEAE-dextran enhancement of polynucleotide induction of interferon. Proc Soc Exp Biol Med (1971) 0.94
Prophylactic control of simian hemorrhagic fever in monkeys by an interferon inducer, polyriboinosinic-polyribocytidylic acid-poly-L-lysine. J Infect Dis (1976) 0.91
Studies on poly I:C toxicity in experimental animals. Toxicol Appl Pharmacol (1972) 0.90
Effect of interferon on togavirus and arenavirus infections of animals. Tex Rep Biol Med (1977) 0.89
Polyinosinic-polycytidylic acid inhibits chemically induced tumorigenesis in mouse skin. Science (1970) 0.88
Dactinomycin: relative resistance of green monkey kidney cell cultures to its action. Proc Soc Exp Biol Med (1967) 0.88
Intracorneal hematoma in Mooren ulceration. Am J Ophthalmol (2000) 0.87
Treatment of intracranial alphavirus infections in mice by a combination of specific antibodies and an interferon inducer. Am J Trop Med Hyg (1995) 0.87
Topical treatment of vaccinia virus infection with an interferon inducer in rabbits. J Infect Dis (1978) 0.86
Effect of interferon on RNA synthesis in Sindbis virus infected cells. Proc Soc Exp Biol Med (1966) 0.86
Epstein-Barr virus and Herpesvirus saimiri: sensitivity to interferons and interferon inducers. J Natl Cancer Inst (1981) 0.86
Effect of interferon treatment on cellular messenger RNA. Proc Natl Acad Sci U S A (1973) 0.85
Immunoprophylactic strategies against respiratory influenza virus infection. Vaccine (2001) 0.85
Protein synthesis by amoebal ribosomes. Nature (1967) 0.85
Sclerokeratitis: an unusual presentation of squamous cell carcinoma of the conjunctiva. Ophthalmology (2001) 0.84
Induction of interferon by preparations of synthetic single-stranded RNA. Proc Natl Acad Sci U S A (1969) 0.84
Antitumor effects of interferon and poly ICLC, and their possible utility as anti-neoplastic agents in man. Tex Rep Biol Med (1983) 0.83
Human adipose-derived mesenchymal stem cells: serial passaging, doubling time and cell senescence. Biotech Histochem (2012) 0.83
Historical overview of the use of polynucleotides in cancer. J Biol Response Mod (1985) 0.83
An effective rabies treatment in exposed monkeys: a single dose of interferon inducer and vaccine. Bull World Health Organ (1979) 0.83
Induction of interferon in vivo and in vitro by polynucleotides and derivatives, and preparation of derivatives. Methods Enzymol (1981) 0.82
Chlorite-oxidized amylose as an adjuvant for interferon production. Infect Immun (1973) 0.82
Postinfection therapy of arbovirus infections in mice. Antimicrob Agents Chemother (1989) 0.82
Interferon induction in primates by stabilized polyriboinosinic acid-polyribocytidylic acid: effect of component size. Infect Immun (1981) 0.82
Modified polyriboinosinic-polyribocytidylic acid complex: induction of serum interferon, fever, and hypotension in rabbits. Antimicrob Agents Chemother (1980) 0.82
Immunochemotherapy for Leishmania donovani infection in golden hamsters: combinatorial action of poly ICLC plus L-arginine and sodium stibogluconate (Stibanate). J Interferon Cytokine Res (1999) 0.82
Immune modulating effects of poly ICLC. Ann N Y Acad Sci (1980) 0.81
Evaluation of polyinosinic-polycytidylic and poly-L-lysine in metastatic breast cancer. Cancer Treat Rep (1986) 0.81
Poly ICLC enhances the antimalarial activity of chloroquine against multidrug-resistant Plasmodium yoelii nigeriensis in mice. J Interferon Cytokine Res (1997) 0.80
Poly ICLC inhibits Plasmodium cynomolgi B malaria infection in rhesus monkeys. J Interferon Cytokine Res (1996) 0.80
Chlamydia trachomatis infections in infants. Mt Sinai J Med (1986) 0.80
Induction of interferon in vivo by polynucleotides. Tex Rep Biol Med (1977) 0.80
Killing of Leishmania donovani amastigotes by poly ICLC in hamsters. J Interferon Cytokine Res (1996) 0.80
Adjuvant effects of low doses of a nuclease-resistant derivative of polyinosinic acid . polycytidylic acid on antibody responses of monkeys to inactivated Venezuelan equine encephalomyelitis virus vaccine. Infect Immun (1979) 0.80
Enhanced therapeutic efficacy of poly(ICLC) and ribavirin combinations against Rift Valley fever virus infection in mice. Antimicrob Agents Chemother (1987) 0.79
Further studies on rabies postexposure prophylaxis in mice: a comparison of vaccine with interferon and vaccine. J Gen Virol (1979) 0.79
Radiation damage and the interferon system. Tex Rep Biol Med (1977) 0.79
A comparison of interferon responses to poly ICLC in males and females. J Interferon Res (1985) 0.79
Response of mouse tumor to interferon inducer and radiation. Int J Radiat Oncol Biol Phys (1985) 0.79
Evaluation of a nuclease-resistant derivative of poly(I) . poly(C) [poly(ICLC)] as a radioprotective agent. Radiat Res (1979) 0.78
Lack of uptake of intact polyriboinosinic-polyribocytidylic acid by cells. Proc Soc Exp Biol Med (1973) 0.78
Poly(I,C)-LC as an interferon inducer in refractory multiple myeloma. J Biol Response Mod (1985) 0.78
Post-exposure prophylaxis of murine rabies with polyinosinic-polycytidylic acid and chlorite-oxidized amylose. Antimicrob Agents Chemother (1974) 0.78
Preliminary trial of poly ICLC in chronic progressive multiple sclerosis. Neurology (1986) 0.78
Cortisol induction by poly ICLC: implications for clinical trials of interferon. Ann Neurol (1988) 0.78
Immune response modifying activity in mice of polyinosinic: polycytidylic acid stabilized with poly-L-lysine, in carboxymethylcellulose [poly-ICLC]. Int J Immunopharmacol (1981) 0.77
Changes in leukocyte recirculation, NK cell activity, and HLA-DR expression in peripheral blood mononuclear cells of MS patients treated with Poly ICLC. Int J Immunopharmacol (1991) 0.77
Histopathological and immunohistochemical studies of lenticules after epikeratoplasty for keratoconus. Br J Ophthalmol (2005) 0.77
The kinetics of interferon induction by poly ICLC in humans. J Interferon Res (1988) 0.77
Interferon assay of high sensitivity. Proc Soc Exp Biol Med (1976) 0.77
Topical polyriboinosinic-polyribocytidylic acid complex in the treatment of recurrent genital herpes. Antimicrob Agents Chemother (1982) 0.77
Protectivity of herpes simplex virus antigens: studies in mice on the adjuvant effect of PICLC and on the dependence of protection on T cell competence. Med Microbiol Immunol (1981) 0.77
Poly ICLC in the treatment of postinfectious demyelinating encephalomyelitis. Arch Neurol (1981) 0.76
Effect of interferon on cellular RNA synthesis and structure. Tex Rep Biol Med (1977) 0.76
Studies on the mechanism of interferon action: characterization of polysome-associated cellular RNAs modified by interferon. Virology (1977) 0.76
Gamma-interferon induction in patients with chronic progressive MS. Neurology (1991) 0.76
Ranking of prophylactic efficacy of poly(ICLC) against Rift Valley fever virus infection in mice by incremental relative risk of death. Antimicrob Agents Chemother (1987) 0.76
Interferon induction by radioprotective mercaptoalkylamines and derived thiophosphates. Infect Immun (1977) 0.75
Modified polyriboinosinic-polyribocytidylic acid complex: modulation of toxicity for rabbits by alterations in components. Antimicrob Agents Chemother (1980) 0.75
A comparison of interferon responses to poly ICLC in males and females. J Interferon Res (1992) 0.75
Bone trauma caused by passive exercise. J Pediatr (1984) 0.75
Meningococcal septic arthritis in an infant. N Y State J Med (1981) 0.75
Alopecia in meralgia paresthetica. J Am Acad Dermatol (1985) 0.75
Polyriboinosinic-polyribocytidylic acid-poly-L-lysine complex [poly(ICL)] without carboxymethylcellulose (CMC): a new primate-effective interferon inducer. Proc Soc Exp Biol Med (1982) 0.75